Tatva Chintan Pharma Chem Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Tatva Chintan Pharma Chem Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹1,083
Per ShareLot Size
13 Shares
Minimum Investment
₹14,079
Issue Size
₹500 Cr
Face Value
₹10
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Tatva Chintan Pharma Chem Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
80.53%
Issue Type
Book Building
ISIN
INE0GK401011
About the Company
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of SDAs, PTCs, electrolyte salts for super capacitor batteries and PASCs. The Company is the largest and only commercial manufacturer of SDAs for zeolites in India and enjoys the second largest position globally. The Company is also one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe.
Industry Overview
The global chemicals market is valued at around USD 4,738 billion and is expected to grow at 6.2% CAGR; reaching USD 6,400 billion by 2024. The Indian chemicals market is valued at USD 166 billion (~4% share in the global chemical industry) and it is expected to reach ~USD 280-300 Bn in the next 5 years, with an anticipated growth of ~12% CAGR. The specialty chemical industry forms ~47% of the domestic chemical market, which is expected to grow at a CAGR of around 11-12% over the same period
Company History
Tatva Chintan Pharma Chem Limited was incorporated as `Tatva Chintan Pharma Chem Private Limited' pursuant to a certificate of incorporation dated June 12, 1996 issued by the Registrar of Companies, Gujarat and Dadra & Nagar Haveli at Ahmedabad ("RoC"). Thereafter, pursuant to the conversion of the Company to a public limited company, the name of the Company was changed to `Tatva Chintan Pharma Chem Limited', and a fresh certificate of incorporation dated February 26, 2021 was issued to the Company by the RoC.
Products & Services
- Quartenary ammonium compounds (which include its SDAs) are widely used in the manufacturing of zeolites. Industrially important zeolites are produced synthetically.
- Phase transfer catalysts facilitates the migration of a reactant from one phase into another where the reaction occurs. The catalyst functions as a detergent for solubilizing the salts into the organic phase
- Electrolyte Salts for super capacitor batteries
- Pharmaceutical and Agrochemicals intermediates and other speciality chemicals
Growth Strategy
- Expand its existing product portfolio
- Further develop its R&D capabilities
- Increase wallet share with existing customers and continued focus to expand customer base
- Expand its existing manufacturing capacities to capitalise on industry opportunities
Customer Base
Merck, Bayer AG, Asian Paints Ltd, Ipox Chemicals KFT, Laurus Labs Ltd, Tosoh Asia Pte. Ltd, SRF Ltd, Navin Fluorine International Ltd, Oriental Aromatics Ltd, Atul Ltd, Otsuka Chemical (I) Pvt Ltd, Meghmani Organics Ltd, Divi's Laboratories Ltd, Hawks Chemical Company Ltd, Firmenich Aromatics Prod. (I) Pvt. Ltd, Jiangsu Guotai Super Power New Materials Co. Ltd, Jade Chem Co. Ltd
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of 4,616,804 equity shares of face value of Rs. 10 each ("equity shares") of Tatva Chintan Pharma Chem Limited ("the company" or the "issuer") for cash at a price of Rs. 1,083 per equity share (including a premium of Rs. 1,073 per equity share) ("offer price" aggregating to Rs. 500 Crores. The offer comprises of a fresh issue of 2,077,562 equity shares aggregating to Rs. 225 Crores ("fresh issue") and an offer for sale of 2,539,242 equity shares aggregating to Rs. 275 Crores, comprising 215,143 equity shares aggregating to Rs. 23.30 Crores by Ajaykumar Mansukhlal Patel, 751,616 equity shares aggregating to Rs. 81.40 Crores by Chintan Nitinkumar Shah, and 674,054 equity shares aggregating to Rs. 73 Crores by Shekhar Rasiklal Somani (collectively the "promoter selling shareholders") and 95,106 equity shares aggregating to Rs. 10.30 Crores by Darshana Nitinkumar Shah, 315,789 equity shares aggregating to Rs. 34.20 Crores by Priti Ajaykumar Patel, 315,789 equity shares aggregating to Rs. 34.20 Crores by Ajay Mansukhlal Patel Huf, 101,570 equity shares aggregating to Rs. 11 Crores by Kajal Shekhar Somani, 10,157 equity shares aggregating to Rs. 1.10 Crores by Shitalkumar Rasiklal Somani, and 60,018 equity shares aggregating to Rs. 6.50 Crores by Samirkumar Rasiklal Somani (collectively The "promoter group selling shareholders", and together with the promoter selling shareholders, the "selling shareholders") (the "offer for sale", and together with the fresh issue, the "offer"). The offer constitutes 20.83% of the post-offer paid-up equity share capital. Offer Price : Rs. 1083 per equity shares of face value of Rs. 10 Each. Anchor Investor offer price : Rs. 1083 per equity share. The offer price is 108.3 times the face value.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- leading manufacturer of structure directing agents and phase transfer catalysts, with consistent quality;
- global presence with a wide customer base across various industries having high entry barriers;
- diversified specialised product portfolio requiring strong technical know-how;
- modern manufacturing facilities with a focus on `green' chemistry processes;
- strong R&D capabilities;
- The continuing impact of the outbreak of the COVID-19 could have a significant effect on company's operations, and could negatively impact its business, revenues, financial condition and results of operations.
- Unplanned slowdowns or shutdowns in our manufacturing operations could have an adverse effect on its business, results of operations and financial condition.
- Company is subject to quality requirements and strict technical specifications and audits by its institutional customers. its failure to comply with the quality standards and technical specifications prescribed by such customers may lead to loss of business from such customers and could negatively impact its reputation, which would have an adverse impact on its business prospects and results of operations.
- Increase in the cost of raw materials could have a material adverse effect on its results of operations and financial conditions.
- Company's business subjects us to risks in multiple countries that could materially adversely affect its business, cash flows, results of operations and prospects.